SGLT-2 inhibitors and risk of 59 long-term health conditions, hospitalisation, and mortality

Clicks: 30
ID: 325605
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #49 of 122 articles by views in european journal of endocrinology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is often the first condition on the pathway to patients developing multiple long-term conditions (MLTC). The impact of sodium-glucose cotransporter 2 inhibitors (SGLT-2i), a key T2DM treatment, on hospitalisation and MLTC progression remains uncertain. METHODS: In this comparative effectiveness study, we emulated a target trial using linked primary care, hospital, and mortality records in England (2012-2023). Adults aged ≥40 years with T2DM initiating SGLT-2i or dipeptidyl peptidase-4 inhibitors (DPP-4i) were included (n=364,522). Outcomes included all-cause mortality, first hospitalisation, number of hospitalisations, and incidence of 59 prespecified long-term conditions across 17 organ systems. Weighted Cox proportional hazards and negative binomial regression models were used to estimate adjusted hazard ratios (aHRs) or adjusted mean differences (aMDs), with 95% CIs and Benjamini-Yekutieli correction for multiple testing. FINDINGS: Compared with DPP-4i, SGLT-2i use was associated with lower risks of all-cause mortality (aHR 0.73, 95% CI 0.71-0.75), first hospitalisation (aHR 0.86, 95% CI 0.85-0.87), and number of hospitalisations (aMD -0.36, 95% CI -0.38 to -0.34; all p<0.001). SGLT-2i initiators had reduced risks for 28 conditions, including dementia, cancer, metabolic dysfunction-associated steatotic liver disease, diabetic foot ulcer, epilepsy, and rheumatoid arthritis. Increased risks were observed for four conditions, including candidiasis and diabetic ketoacidosis. INTERPRETATION: SGLT-2i use in T2DM was associated with significant reductions in mortality, hospitalisation, and MLTC burden. The broad protective effects across multiple organ systems highlight the potential of SGLT-2i to offer a holistic therapeutic strategy in the management of diabetes and its multisystem complications.
Reference Key
openalex_W7203792698 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jingya Wang, Jennifer Cooper, Eleanor Hathaway, Megha Singh, Lei Su, Krishna Gokhale, Steven Wambua, Francesca L. Crowe, Nicola J. Adderley, G Neil Thomas, Graham Lipkin, Lisa J Hill, Indranil Dasgupta, Wasim Hanif, Punith Kempegowda, Kesavapillai Subramonian, Kar Keung Cheng, Thomas Jackson, Konstantinos A. Toulis, Krishnarajah Nirantharakumar
Are you one of these authors? Claim your profile
Journal european journal of endocrinology
Year 2026
DOI
10.1093/ejendo/lvag156
URL
https://doi.org/10.1093/ejendo/lvag156
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.